Roche Holding AG (RO) - Total Liabilities
Based on the latest financial reports, Roche Holding AG (RO) has total liabilities worth CHF62.82 Billion CHF as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Roche Holding AG - Total Liabilities Trend (1998–2025)
This chart illustrates how Roche Holding AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Roche Holding AG Competitors by Total Liabilities
The table below lists competitors of Roche Holding AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CBRE Group Inc Class A
NYSE:CBRE
|
USA | $19.27 Billion |
|
Diageo plc
MX:DEON
|
Mexico | MX$36.14 Billion |
|
Ciena Corp
NYSE:CIEN
|
USA | $3.10 Billion |
|
Compagnie de Saint-Gobain S.A.
PA:SGO
|
France | €36.18 Billion |
|
Edwards Lifesciences Corp
NYSE:EW
|
USA | $3.07 Billion |
|
MicroStrategy Incorporated
NASDAQ:MSTR
|
USA | $10.60 Billion |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
China | CN¥43.89 Billion |
|
Rockwell Automation Inc
NYSE:ROK
|
USA | $7.43 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Roche Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.20 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roche Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roche Holding AG (1998–2025)
The table below shows the annual total liabilities of Roche Holding AG from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF62.82 Billion | -4.29% |
| 2024-12-31 | CHF65.64 Billion | +14.75% |
| 2023-12-31 | CHF57.20 Billion | +1.90% |
| 2022-12-31 | CHF56.14 Billion | -12.25% |
| 2021-12-31 | CHF63.97 Billion | +37.97% |
| 2020-12-31 | CHF46.37 Billion | -1.82% |
| 2019-12-31 | CHF47.22 Billion | -1.93% |
| 2018-12-31 | CHF48.15 Billion | +1.01% |
| 2017-12-31 | CHF47.67 Billion | -5.45% |
| 2016-12-31 | CHF50.42 Billion | -3.90% |
| 2015-12-31 | CHF52.46 Billion | -2.81% |
| 2014-12-31 | CHF53.98 Billion | +31.90% |
| 2013-12-31 | CHF40.93 Billion | -14.87% |
| 2012-12-31 | CHF48.08 Billion | +2.09% |
| 2011-12-31 | CHF47.09 Billion | -4.59% |
| 2010-12-31 | CHF49.36 Billion | -24.24% |
| 2009-12-31 | CHF65.15 Billion | +192.59% |
| 2008-12-31 | CHF22.27 Billion | -10.49% |
| 2007-12-31 | CHF24.88 Billion | -9.87% |
| 2006-12-31 | CHF27.60 Billion | -0.08% |
| 2005-12-31 | CHF27.62 Billion | +11.46% |
| 2004-12-31 | CHF24.78 Billion | -18.27% |
| 2003-12-31 | CHF30.32 Billion | -20.67% |
| 2002-12-31 | CHF38.22 Billion | -7.72% |
| 2001-12-31 | CHF41.42 Billion | +10.45% |
| 2000-12-31 | CHF37.50 Billion | -7.25% |
| 1999-12-31 | CHF40.43 Billion | +22.28% |
| 1998-12-31 | CHF33.06 Billion | -- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more